Vaccines

12 Sep 2022 PDC*line Pharma presents first clinical results from Phase I/II trial with PDC*lung01 at ESMO 2022
09 Sep 2022 Genexine’s First-in-Class Therapeutic DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer
06 Sep 2022 CanSinoBIO's Convidecia Air™ Receives Approval in China
02 Sep 2022 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
02 Sep 2022 Aston Sci. Receives IND Approval from U.S. FDA for Phase 2 Clinical Trial of the Therapeutic Cancer Vaccine AST-301 in Patients with HER2 1+/2+ Breast Cancer
01 Sep 2022 Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
01 Sep 2022 Daiichi Sankyo Announces Initiation of Phase 3 Trial of mRNA COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
31 Aug 2022 Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
31 Aug 2022 IAVI Announces First Vaccinations at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate
31 Aug 2022 Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
27 Aug 2022 Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
25 Aug 2022 Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
23 Aug 2022 Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
19 Aug 2022 CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
16 Aug 2022 Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
13 Aug 2022 Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
09 Aug 2022 Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
03 Aug 2022 Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates
28 Jul 2022 Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
26 Jul 2022 Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox
26 Jul 2022 FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
22 Jul 2022 Blue Lake Biotechnology Announces First Participant Dosed in a Phase 1 Clinical Trial of Its BLB-201 Intranasal RSV Vaccine
21 Jul 2022 HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate
20 Jul 2022 Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma
14 Jul 2022 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top